On 25 Sept 2026, NT PHARMA (01011.HK) said an arbitration award orders it and jointly liable parties to pay ~RMB75m; it has moved to set aside the award.
On 25 September 2026, Shanghai Zhida Technology Development Co., Ltd. (02650.HK) announced that the placing has been completed, with an aggregate of 23,670,550 placing shares successfully placed at HKD 8.77 per share to not fewer than six placees, raising net proceeds of approximately HKD 203.44 million.
On 25 September 2026, RobotPhoenix Intelligent Technology Co., Ltd. (06871.HK) announced that it has entered into a strategic cooperation agreement with CAS Space Technology Co., Ltd., under which the two parties will establish a long-term strategic cooperative relationship and explore cooperation in research collaboration, industrial ecosystem development, supply chain coordination and talent exchange in space manufacturing and intelligent manufacturing for the commercial space industry, with the agreement valid for three years.
On 25 September 2026, Red Avenue New Materials Group Co., Ltd. (09607.HK) announced that the offer price for its global offering has been determined at HKD 44.00 per H share.
PTL (603659.SH) said on 25 September it received a CSRC filing notice (Guohehan [2026] No. 2281) to issue up to 269,330,400 overseas-listed ordinary shares and list in Hong Kong, still subject to approvals.
Capchem (300037.SZ) said on 24 September it received a CSRC filing notice (Guohehan [2026] No. 2282) to issue up to 96,329,900 overseas-listed ordinary shares and list on the HKEX Main Board, still subject to approvals.
On 24 September 2026, Orbbec Inc. filed for a Main Board listing on the HKEX, with Goldman Sachs (Asia) and Haitong International as joint sponsors.
On 24 September 2026, CHINA CRSC (03969.HK) said it won three major railway projects worth a combined RMB976 million, about 2.81% of its 2025 audited revenue.
On 24 Sept 2026, CSPC PHARMA (01093.HK) said its Phase III trial of Becotatug (JMT101) plus osimertinib in EGFR ex20ins NSCLC met the primary endpoint.
On September 23, 2026, Hang Seng Indexes Company launched eight new indexes in a single day, including three in the Hang Seng TECH Composite Index series—the Hang Seng TECH Composite Index, the Hang Seng TECH Composite LargeCap Index and the Hang Seng TECH Composite MidSmallCap Index.
On 24 Sep 2026, UNITED LAB (03933.HK) said NMPA accepted the filing for its IDegLira once-daily diabetes shot, the first such biosimilar application in China.
On 24 Sep 2026, HANSOH PHARMA (03692.HK) said NMPA accepted the NDA for HS-20093, its B7-H3-targeting ADC, to treat osteosarcoma patients after 2+ prior lines.
On 24 Sep 2026, YH ENT (02306.HK) agreed to buy the remaining 46.55% of Yuhuatongxing for RMB 4mn, making it wholly-owned, and ended the Shenzhen Yiqi pact.
On 24 Sep 2026, GOLDENSOLAR (01121.HK) said its Dometic solar awning project entered field testing; cell efficiency verified at 28.2%; no supply contract yet.
On 24 Sep 2026, OCT (ASIA) (03366.HK) plans to sell 100% of OCT (Changshu) Investment by tender at a base price of at least RMB 90.45mn, a major transaction.
On September 24, Hong Kong stocks closed lower, with the HSI down 0.29%. DMALL led Stock Connect, up 15.62%, while southbound net buying was HK$2.900 billion.
